A Multicenter Phase II, Open Label, Single Arm Study to Evaluate the Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Acronyms REALISE
- Sponsors Novartis Pharmaceuticals
- 11 Mar 2018 Planned End Date changed from 23 Dec 2018 to 15 Feb 2019.
- 11 Mar 2018 Planned primary completion date changed from 23 Dec 2018 to 28 Mar 2018.
- 16 Jun 2017 Planned End Date changed from 21 Dec 2018 to 22 Dec 2018.